| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FRSB; PheHB; PheRS; FARSLB; HSPC173 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human FARSB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FARSB抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*Autoantibodies against phenylalanyl-tRNA synthetase (FARSB) in patients with interstitial lung disease and dermatomyositis*
**作者**：Hirakata M, et al.
**摘要**：该研究在特发性间质性肺病和皮肌炎患者血清中检测到抗FARSB自身抗体，提示其可能作为新型生物标志物，与疾病活动性和肺纤维化进展相关。
2. **文献名称**：*Structural basis of FARSB activation in phenylalanine biosynthesis by cryo-EM*
**作者**：Luo J, et al.
**摘要**：通过冷冻电镜解析FARSB的分子结构，并利用特异性抗体定位其催化活性位点，阐明了其在苯丙氨酸-tRNA合成中的构象调控机制。
3. **文献名称**：*FARSB overexpression promotes tumor invasion and correlates with poor prognosis in colorectal cancer*
**作者**：Wang Y, et al.
**摘要**：研究通过免疫组化(使用FARSB抗体)发现结直肠癌中FARSB高表达，其水平与肿瘤转移和患者生存率下降显著相关，提示其致癌潜力。
*注：以上文献为示例性质，实际引用时请核对真实来源及内容准确性。若需具体文献，建议通过PubMed或Web of Science以“FARSB antibody”或“phenylalanyl-tRNA synthetase beta subunit”为关键词检索。*
The phenylalanyl-tRNA synthetase beta subunit (FARSB) is a crucial component of the cytosolic phenylalanyl-tRNA synthetase (FARS) complex, responsible for charging tRNA^Phe with phenylalanine during protein synthesis. As part of the aminoacyl-tRNA synthetase (ARS) family, FARSB works in conjunction with the alpha subunit (FARSA) to form a functional heterotetramer (α2β2). Beyond its canonical role in translation, FARSB has been implicated in non-canonical functions, including inflammatory signaling and angiogenesis.
FARSB antibodies are essential tools for studying its expression patterns, subcellular localization, and interaction partners. Research has linked FARSB dysregulation to various pathologies: elevated FARSB levels correlate with tumor progression in certain cancers, while mutations are associated with mitochondrial encephalopathies and pulmonary hypertension. These antibodies enable applications such as Western blotting, immunohistochemistry, and immunofluorescence to explore its role in cellular homeostasis and disease mechanisms.
Recent studies also highlight FARSB's potential as a biomarker or therapeutic target, particularly in cancers with tRNA synthetase dysregulation. Commercial FARSB antibodies are typically validated for species specificity (human, mouse, rat) and tested in multiple experimental models to ensure reproducibility. Understanding FARSB biology remains critical for unraveling tRNA synthetase-related diseases and developing targeted interventions.
×
